Skip to content

Feasibility study of bladder training app and urination prediction device for women having symptoms of urinary urgency or urine leakage

Feasibility study of bladder training app and urination prediction device for women having symptoms of urinary urgency or urine leakage - Feasibility study of bladder training app and urination prediction device for women having symptoms of urinary urgency or urine leakage

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000051659
Enrollment
10
Registered
2023-07-20
Start date
2023-07-20
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

urinary incontinence, Overactive bladder

Interventions

bladder training app and urination prediction device

Sponsors

Save Medical Corporation
Lead Sponsor

Eligibility

Sex/Gender
Female

Inclusion criteria

Inclusion criteria: 1)Women between the ages of 20 and 64 at the time consent is obtained 2)Participants whose urinary frequency averaged between 8 and 14 times per 24 hours in the urinary status recorded on the app during the observation period 3)Participants who had urinary urgency or leakage with urinary urgency at least once per 24 hours in the urinary status recorded on the app during the observation period. 4)Participants who can attach DFree and perform bladder training for a certain period 5)Participants who can use online conferencing tools and LINE 6)Participants who have an iPhone supported by iOS13 or higher (iPhone 6s or higher)

Exclusion criteria

Exclusion criteria: 1)Participants who have hematuria 2)Participants who have discomfort or pain associated with urination 3)Participants who have a residual urine 4)Participants who are taking medication for overactive bladder 5)Participants with a history of pelvic surgery or radiation therapy 6)Participants with a history of neurological disease 7)Participants who are using estrogen preparations 8)Participants with the following diseases (diabetes, spina bifida, uterine fibroids, severe constipation, peripheral neuropathy) 9)Pregnant participants 10)Participants who are using implantable medical devices (pacemakers, defibrillators, etc.) 11)Participants whose records of DFree did not reach zero after urinating during the observation period 12)Participants who are considered as inappropriate for this study by the research collaborating physician

Design outcomes

Primary

MeasureTime frame
Change from baseline (observation period) in average daily frequency of urination at 8 weeks of treatment period

Countries

Japan

Contacts

Public ContactAyako Tamura

Save Medical Corporation Business Development Department

bd@savemedical.jp050-3612-4524

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026